GlassScriptPhysician profile
Pooja N Patel
NPI 1801100821
$3,522.69
in general payments reported to CMS, 2019-2025
25 companies · $2,481 in 2025
The $2,481 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.46 · 2022: $180 · 2023: $484 · 2024: $365 · 2025: $2,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,311 · Education: $19.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,311.18 |
| Education | $19.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $748.96 | 2022-2025 | Evenity, Krystexxa, Tavneos |
| Abbvie INC. | $531.75 | 2022-2025 | |
| Ucb, INC. | $447.02 | 2025 | Bimzelx |
| Alexion Pharmaceuticals, INC. | $382.18 | 2024-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.02 | 2023-2025 | Ofev |
| Novartis Pharmaceuticals Corporation | $176.36 | 2024-2025 | |
| Glaxosmithkline, LLC. | $162.96 | 2022-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $124.21 | 2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $121.12 | 2025 | Acthar |
| Pfizer INC. | $99.82 | 2025 | |
| Genzyme Corporation | $82.88 | 2024 | |
| Aurinia Pharma U.S., INC. | $65.83 | 2025 | Lupkynis |
| Csl Behring | $36.27 | 2023 | Kcentra |
| Tolmar, INC. | $29.47 | 2024-2025 | Jatenzo |
| Takeda Pharmaceuticals U.S.A., INC. | $29.33 | 2025 | Cuvitru |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $26.02 | 2025 | |
| Janssen Biotech, INC. | $24.31 | 2025 | Tremfya |
| Abbott Laboratories | $23.97 | 2025 | Eterna |
| E.R. Squibb & Sons, L.L.C. | $22.73 | 2025 | Orencia |
| Lilly USA, LLC | $22.72 | 2025 | Taltz |
| Tonix Medicines, INC. | $22.36 | 2025 | Tonmya |
| Merck Sharp & Dohme LLC | $20.19 | 2025 | Verquvo |
| Sobi, INC | $19.25 | 2025 | |
| Organon LLC | $17.50 | 2025 | |
| Livanova USA, INC. | $12.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pooja Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.